This week in therapeutics




Licensing status

Publication and contact information


Cervical cancer

Histone deacetylase 6 (HDAC6)

Patient sample and cell culture studies suggest inhibiting HDAC6 could help treat cervical cancer. In two human cervical cell lines, small interfering RNA against HDAC6 decreased cell proliferation and migration compared with control siRNA. In samples from patients with cervical cancer, expression of HDAC6 and its downstream mediators was higher in cancer cells than in adjacent noncancerous epithelial cells. Next steps could include studying HDAC6 inhibitors in a mouse xenograft model for cervical cancer.
Acetylon Pharmaceuticals Inc.'s ACY-1215, an oral selective HDAC6 inhibitor, is in Phase I/II testing for multiple myeloma (MM).

At least two other companies have HDAC6 inhibitors in preclinical development to treat various cancers and inflammation.

SciBX 6(25); doi:10.1038/scibx.2013.622
Published online June 27, 2013

Patent and licensing status unavailable

Chen, Y.-T. et al. Cancer Res.; published online May 22, 2013;
Contact: Meng-Ru Shen, National Cheng Kung University Hospital, Tainan, Taiwan